By
19 min ago 2 min read
Italy-based Cavagna Group (Cavagna) will adopt Gaslive as the global identity for its healthcare range, which includes solutions for respiratory therapy, oxygen therapy and sleep medicine.
The move aims to consolidate the company’s healthcare portfolio under a single global identity as the company looks to strengthen its presence in the respiratory care market.
Rather than marketing products under multiple names, it is likely that the Gaslive brand will serve as the umbrella for its medical gas technologies.
According to Miriam Cavagna, Head of Marketing and Communications, the brand – which Cavagna acquired in 2024 – was chosen due to its credibility and recognition value within the healthcare sector.
“Bringing our range of respiratory therapy and sleep medicine products together under a single brand identity will enable us to present ourselves to international markets with an even clearer, more consistent and distinctive offering,” she said.
The company provides a range of healthcare solutions such as the Viproxy line of integrated pressure regulator valves and pin-index cylinder valves for oxygen and other medical gases.
The rebrand comes as demand for medical gas equipment continues to grow. The global medical gas valve market was valued at around $1.5bn in 2025 and is forecast to reach approximately $2.6bn by 2033, driven by rising demand for respiratory care, ageing populations and expanding healthcare infrastructure.
Although the rebrand is global, Gaslive is particularly well-established in South America. Originating in Brazil, it has since expanded operations into Colombia.
